|
|
||||||||
, by C
Inactivator1From the Department of Molecular Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037
Abstract
In order to clarify its mechanism of disassembly, the first component of human complement, C1, was reconstituted from C1q, 125I-C1r, and 131I-C1s. This radiolabeled C1 bound tightly to aggregated IgG covalently linked to Sepharose 4B. The subsequent addition of C
inactivator (C
-In) led to the rapid release of equimolar quantitites of 125I-C1
and 131I-C1
from the agg IgG. SDS-PAGE analyses of such eluates showed that one C
-In molecule was associated with each C1
polypeptide chain and another C
-In molecule was bound to each C1
polypeptide chain. The released C1
, C1
, and C
-In co-sedimented in sucrose density gradients with a rate of 9S and monospecific anti-C1
pelleted all three proteins. Therefore, C1
, C1
, and C
-In, in a molar ratio of 1:1:2, respectively, are released from C
as a complex.
An analogous 9S complex containing C1
, C1
, and C
-In was generated in normal human serum after incubation with activators of the classical complement pathway. The C1
C1
(C
-In) complexes generated in both serum and the purified system were stable in the presence of EDTA.
A diffusion coefficient of 2.3 x 10-7 cm2/sec was determined for the C1
C1
(C
-In) complex from its behavior on gel filtration. An m.w. of 330,000 was then calculated from its sedimentation and diffusion coefficients. This m.w. is consistent with the value of 382,000 for a molecule of composition C1
C1
(C
-In)2 obtained by summing the weights of the subunits. These results indicate that C1-In efficiently disassembles C
, thereby releasing two C1
C1
(C
-In)2 complexes per C
molecule.
Footnotes
1 This is publication No. 1758 from the Research Institute of Scripps Clinic. This work was supported by United States Public Health Service Grants CA 14692, AI 07007, AI 14502, 1 S07 RR 05514 from the National Institutes of Health and Grant-in-Aid 77-941 from the American Heart Association.
This article has been cited by other articles:
![]() |
C. Caliezi, W. A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C. E. Hack C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in the Treatment of Diseases Other Than Hereditary Angioedema Pharmacol. Rev., March 1, 2000; 52(1): 91 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Tas, L. B. Klickstein, S. F. Barbashov, and A. Nicholson-Weller C1q and C4b Bind Simultaneously to CR1 and Additively Support Erythrocyte Adhesion J. Immunol., November 1, 1999; 163(9): 5056 - 5063. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. van den Berg, M. C. Faber-Krol, S. van Wetering, P. S. Hiemstra, and M. R. Daha Inhibition of Activation of the Classical Pathway of Complement by Human Neutrophil Defensins Blood, November 15, 1998; 92(10): 3898 - 3903. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Storm, J. Herz, P. Trinder, and M. Loos C1 Inhibitor-C J. Biol. Chem., December 5, 1997; 272(49): 31043 - 31050. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |